Molecular Biology and Clinical Mitigation of Cancer Treatment-Induced Neuropathy

Molecular Biology and Clinical Mitigation of Cancer Treatment-Induced Neuropathy

Show other versions (1)

Disruption of microtubule function is the antitumor mechanism of several classes of drugs used to treat cancer today. However, the significant beneficial effect on tumor outcomes is frequently counterbalanced by neurotoxic complications. Despite an abundance of scientific data, our understanding of...

Full description

Bibliographic Details
Main Authors: Gerald M. Higa, Corbin Sypult
Format: Article
Language:English
Published: SAGE Publishing 2016-01-01
Series:Clinical Medicine Insights: Oncology
Online Access:https://doi.org/10.4137/CMO.S32810
id doaj-b3f1a0b8fa0246f08184c0a1da773d28
record_format Article
spelling doaj-b3f1a0b8fa0246f08184c0a1da773d282020-11-25T03:44:29ZengSAGE PublishingClinical Medicine Insights: Oncology1179-55492016-01-011010.4137/CMO.S32810Molecular Biology and Clinical Mitigation of Cancer Treatment-Induced NeuropathyGerald M. Higa0Corbin Sypult1Schools of Pharmacy and Medicine, West Virginia University, Morgantown, WV, USA.School of Pharmacy, West Virginia University, Morgantown, WV, USA.Disruption of microtubule function is the antitumor mechanism of several classes of drugs used to treat cancer today. However, the significant beneficial effect on tumor outcomes is frequently counterbalanced by neurotoxic complications. Despite an abundance of scientific data, our understanding of the biological mechanisms underlying this toxic reaction remains unclear, further hindering attempts to identify and develop effective preventive strategies. The primary goals of this review are to: (1) provide insight regarding the biology of the microtubule, (2) analyze the molecular and biochemical pathways that may be involved in the development of neurotoxicity, and (3) propose a unifying concept linking drug-induced neuropathy, microtubule dysfunction, and vitamin D.https://doi.org/10.4137/CMO.S32810
collection DOAJ
language English
format Article
sources DOAJ
author Gerald M. Higa
Corbin Sypult
spellingShingle Gerald M. Higa
Corbin Sypult
Molecular Biology and Clinical Mitigation of Cancer Treatment-Induced Neuropathy
Clinical Medicine Insights: Oncology
author_facet Gerald M. Higa
Corbin Sypult
author_sort Gerald M. Higa
title Molecular Biology and Clinical Mitigation of Cancer Treatment-Induced Neuropathy
title_short Molecular Biology and Clinical Mitigation of Cancer Treatment-Induced Neuropathy
title_full Molecular Biology and Clinical Mitigation of Cancer Treatment-Induced Neuropathy
title_fullStr Molecular Biology and Clinical Mitigation of Cancer Treatment-Induced Neuropathy
title_full_unstemmed Molecular Biology and Clinical Mitigation of Cancer Treatment-Induced Neuropathy
title_sort molecular biology and clinical mitigation of cancer treatment-induced neuropathy
publisher SAGE Publishing
series Clinical Medicine Insights: Oncology
issn 1179-5549
publishDate 2016-01-01
description Disruption of microtubule function is the antitumor mechanism of several classes of drugs used to treat cancer today. However, the significant beneficial effect on tumor outcomes is frequently counterbalanced by neurotoxic complications. Despite an abundance of scientific data, our understanding of the biological mechanisms underlying this toxic reaction remains unclear, further hindering attempts to identify and develop effective preventive strategies. The primary goals of this review are to: (1) provide insight regarding the biology of the microtubule, (2) analyze the molecular and biochemical pathways that may be involved in the development of neurotoxicity, and (3) propose a unifying concept linking drug-induced neuropathy, microtubule dysfunction, and vitamin D.
url https://doi.org/10.4137/CMO.S32810
work_keys_str_mv AT geraldmhiga molecularbiologyandclinicalmitigationofcancertreatmentinducedneuropathy
AT corbinsypult molecularbiologyandclinicalmitigationofcancertreatmentinducedneuropathy
_version_ 1724514631376961536

Similar Items